 fibrinolytic activity platelet function hypertension Possible influence calcium antagonism patients mild hypertension days placebo age- gender-matched group healthy volunteers platelet aggregability fibrinolytic activity hypertensives calcium antagonist isradipine months Blood determinations platelet aggregation fibrinolytic activity weeks months treatment Platelet aggregation hypertensives controls lowering adenosine diphosphate ADP value irreversible aggregation Tissue-plasminogen activator t-PA activity hypertensives controls therapy platelet aggregation t-PA activity present data fibrinolytic activity platelet aggregation mild hypertension blood pressure-lowering effect isradipine thromboembolic diseases platelet function fibrinolytic activity